National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

From the 6/11/2021 release of VAERS data:

Found 239 cases where Symptom is Crohn's disease



Case Details

This is page 6 out of 24

Result pages: prev   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15   next


VAERS ID: 626353 (history)  
Form: Version 1.0  
Age: 21.0  
Sex: Female  
Location: New Jersey  
Vaccinated:1998-01-01
Onset:1998-06-01
   Days after vaccination:151
Submitted: 2016-03-09
   Days after onset:6491
Entered: 2016-03-09
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
ANTH: ANTHRAX (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / IM

Administered by: Military       Purchased by: Military
Symptoms: Colitis ulcerative, Crohn's disease, Diverticulitis, Fatigue, Irritable bowel syndrome, Thyroid disorder
SMQs:, Gastrointestinal premalignant disorders (narrow), Gastrointestinal ulceration (narrow), Gastrointestinal nonspecific inflammation (broad), Ischaemic colitis (broad), Hypothyroidism (broad), Hyperthyroidism (broad), Noninfectious diarrhoea (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? Yes
Recovered? No
Office Visit? No
ER Visit? Yes
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: No
Preexisting Conditions: None
Allergies:
Diagnostic Lab Data: Crohns disease; Ulcerative colitis; Diverticulitis; Thyroid deficiency
CDC Split Type:

Write-up: Started having IBS. Fatigued.


VAERS ID: 627981 (history)  
Form: Version 1.0  
Age: 11.0  
Sex: Male  
Location: Virginia  
Vaccinated:2015-12-22
Onset:0000-00-00
Submitted: 2016-03-18
Entered: 2016-03-18
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. - / 3 UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Abdominal pain, Antibody test negative, Appendicectomy, Biopsy site unspecified abnormal, Crohn's disease, Endotracheal intubation, Granuloma, Inflammation
SMQs:, Acute pancreatitis (broad), Angioedema (broad), Retroperitoneal fibrosis (broad), Gastrointestinal premalignant disorders (narrow), Malignancy related therapeutic and diagnostic procedures (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Ischaemic colitis (broad), Respiratory failure (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? Yes
ER or Doctor Visit? No
Hospitalized? Yes, 3 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Biopsy (in December 2015): Showing chronic inflammation with occasional granuloma. Antibody test (unspecified date): Negative titers
CDC Split Type: WAES1603USA007553

Write-up: This spontaneous report was received from a registered nurse referring to a 11 year old male patient. The patient''s concurrent conditions and medical history were not provided. The patient did not have drug reactions or allergies. On 02-DEC-2005, the patient was vaccinated with a first dose of VARIVAX (Merck), and 13-AUG-2015 he was vaccinated with the second dose of VARIVAX (Merck) (strength, dose, route, anatomical location, lot number and expiration date were not provided). The patient did not take any concomitant medications. The nurse reported that since an unspecified date, (over the past several years), the patient was complaining of abdominal pain, subsequently, on 02-DEC-2015, the patient was hospitalized for 48 hours, where an appendectomy, requiring intubation was performed. During the procedure, a biopsy was performed which showed a chronic inflammation with occasional granuloma; due to this finding, the patient was diagnosed with Crohn''s Disease (the patient would began an unspecified immunosuppressive therapy agent in the near future). It was also reported, that due to negative titers, the patient was administered a third dose of VARIVAX (Merck) on 22-DEC-2015. The nurse considered the event of appendectomy to be serious event, as it required intubation during surgery. At the time of the report, the patient had not recovered from the adverse events. Additional information has been requested.


VAERS ID: 637253 (history)  
Form: Version 1.0  
Age: 11.0  
Sex: Male  
Location: Illinois  
Vaccinated:2016-05-19
Onset:2016-05-20
   Days after vaccination:1
Submitted: 2016-05-21
   Days after onset:1
Entered: 2016-05-21
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MNQ: MENINGOCOCCAL CONJUGATE (MENACTRA) / SANOFI PASTEUR U5185BA / 1 LA / UN
PPV: PNEUMO (PNEUMOVAX) / MERCK & CO. INC. L040053 / 1 RA / UN
TDAP: TDAP (ADACEL) / SANOFI PASTEUR U5316AA / 1 LA / UN

Administered by: Private       Purchased by: Private
Symptoms: Condition aggravated, Crohn's disease, Erythema, Fatigue, Immunodeficiency, Skin warm, Swelling
SMQs:, Anaphylactic reaction (broad), Angioedema (broad), Gastrointestinal premalignant disorders (narrow), Ischaemic colitis (broad), Haemodynamic oedema, effusions and fluid overload (narrow), Hypersensitivity (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: REMICADE
Current Illness: Crohn''s disease
Preexisting Conditions: Crohn''s disease
Allergies:
Diagnostic Lab Data: None
CDC Split Type:

Write-up: PNEUMOVAX 23 given Rt deltoid 5/19/16. Pt has Crohn''s - immunocompromised. 5/21/16 6" red raised warm reaction Rt arm/fatigue.


VAERS ID: 644609 (history)  
Form: Version 1.0  
Age:   
Sex: Female  
Location: Unknown  
Vaccinated:2016-01-01
Onset:0000-00-00
Submitted: 2016-07-23
Entered: 2016-07-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV9: HPV (GARDASIL 9) / MERCK & CO. INC. - / 1 UN / IM

Administered by: Other       Purchased by: Other
Symptoms: Crohn's disease, Inflammatory bowel disease
SMQs:, Gastrointestinal premalignant disorders (narrow), Ischaemic colitis (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: WAES1607USA008285

Write-up: This spontaneous report concerning a currently 10 years old female patient was received from a nurse practitioner. No concurrent conditions and medical history were provided. On an unknown date in January 2016, reported as approximately six months ago, the patient was vaccinated with the first dose of GARDASIL 9, one dose (lot number and expiration date were not provided), by intramuscular route. There were no concomitant medications reported. On an unknown date in 2016, the patient experienced Crohn''s disease. The reporter stated that, since the patient''s first dose of GARDASIL 9, she was started a treatment with REMICADE for her Crohn''s disease and she was responded well to it. No product quality complain was involved. At the time of reporting, the outcome of the event of inflammatory bowel disease was unknown. The causality between the event of inflammatory bowel disease and GARDASIL 9 was not assessed. Upon internal review, the event of inflammatory bowel disease was considered medically significant. Additional information has been requested.


VAERS ID: 650726 (history)  
Form: Version 1.0  
Age: 58.0  
Sex: Female  
Location: Minnesota  
Vaccinated:2016-08-26
Onset:2016-08-27
   Days after vaccination:1
Submitted: 2016-09-01
   Days after onset:5
Entered: 2016-09-01
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
FLU4: INFLUENZA (SEASONAL) (FLUZONE QUADRIVALENT) / SANOFI PASTEUR U1678AE / UNK AR / IM

Administered by: Other       Purchased by: Private
Symptoms: Computerised tomogram abdomen abnormal, Crohn's disease, Diarrhoea
SMQs:, Retroperitoneal fibrosis (broad), Pseudomembranous colitis (broad), Gastrointestinal premalignant disorders (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Ischaemic colitis (broad), Noninfectious diarrhoea (narrow), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? Yes
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: clonazepam; simvastatin; amitriptyline
Current Illness: None
Preexisting Conditions: None
Allergies:
Diagnostic Lab Data: Patient received abdominal CT scan on 9-1-16 was diagnosed with Crohn''s disease
CDC Split Type:

Write-up: The morning following vaccine administration the patient got diarrhea.


VAERS ID: 681745 (history)  
Form: Version 1.0  
Age: 62.0  
Sex: Female  
Location: Washington  
Vaccinated:2016-10-08
Onset:2016-11-02
   Days after vaccination:25
Submitted: 2017-02-07
   Days after onset:97
Entered: 2017-02-07
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
FLUX: INFLUENZA (SEASONAL) (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK UN / UN

Administered by: Other       Purchased by: Other
Symptoms: Apparent death, Coma, Crohn's disease, Hernia repair, Nasopharyngitis, Pancreatitis, Respiratory failure, Total lung capacity decreased
SMQs:, Anaphylactic reaction (broad), Acute pancreatitis (narrow), Hyperglycaemia/new onset diabetes mellitus (broad), Neuroleptic malignant syndrome (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Gastrointestinal premalignant disorders (narrow), Acute central respiratory depression (narrow), Guillain-Barre syndrome (broad), Noninfectious encephalitis (broad), Noninfectious encephalopathy/delirium (broad), Noninfectious meningitis (broad), Ischaemic colitis (broad), Hypersensitivity (broad), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad), Hypokalaemia (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, 16 days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: COMBIVENT; Prednisone; SPIRIVA; FLOVENT; VENTOLIN HFA
Current Illness: Unknown
Preexisting Conditions: Tobacco user, the patient had quit smoking 5 years before reporting date
Allergies:
Diagnostic Lab Data:
CDC Split Type: US2017003102

Write-up: This case was reported by a consumer via call center representative and described the occurrence of respiratory failure in a 62-year-old female patient who received FLOVENT inhaler (batch number 3V4X, expiry date 31st October 2017) for product used for unknown indication. Co-suspect products included VENTOLIN HFA inhaler (batch number 9E6S, expiry date 31st January 2018) for product used for unknown indication. On an unknown date, the patient started FLOVENT 2 puff(s) at an unknown frequency and VENTOLIN HFA 2 puff(s) at an unknown frequency. On an unknown date, an unknown time after starting FLOVENT and VENTOLIN HFA, the patient experienced respiratory failure (serious criteria hospitalization and GSK medically significant), coma (serious criteria hospitalization and GSK medically significant), near death experience (serious criteria hospitalization and GSK medically significant), hernia repair (serious criteria GSK medically significant), Crohn''s (serious criteria GSK medically significant) and cold. The action taken with FLOVENT was unknown. The action taken with VENTOLIN HFA was unknown. On an unknown date, the outcome of the respiratory failure, coma, near death experience, hernia repair, Crohn''s and cold were unknown. The reporter considered the respiratory failure, coma, near death experience, hernia repair, Crohn''s and cold to be unrelated to FLOVENT. It was unknown if the reporter considered the respiratory failure, coma, near death experience, hernia repair, Crohn''s and cold to be related to VENTOLIN HFA. Additional details: The patient experienced pulmonary failure while taking FLOVENT HFA and VENTOLIN. As a result, the patient was hospitalized and went into a coma and almost died. The patient had also experienced a cold while on FLOVENT and VENTOLIN. The patient had surgery to repair a hernia while on VENTOLIN but was not sure if she was on FLOVENT at that time. The patient also had Crohn''s surgery while on VENTOLIN. Follow-up information was received from a consumer via call center representative on 10 January 2017. Patient called the response center back to confirm they were on the FLOVENT inhaler prior to the previously described adverse events. Patient did not believe the FLOVENT contributed to the adverse events; however the patient was on the medication when events occurred. No further information was provided. Follow up information was received from consumer via call center representative on 31st January 2017: The reporter''s contact details were updated. The patient was a smoker and she had quit smoking 5 years before reporting date. The patient explained that she believed that the Influenza vaccine Quadrivalent that she received on 8th October 2016 with the COMBIVENT medication, Prednisone, as well as getting over her cold at the time of her vaccine and her Crohn''s disease might had all contributed to her present condition, rather than the FLOVENT medication. The product name of the flu vaccine was unknown. The patient also reported that she was on oxygen full time and only had 8 to 10 percent lung capacity. The patient was diagnosed with pancreatitis when she was hospitalized from 2nd November 2016 to 18th November 2016. The patient would not returning the follow up adverse event letter that she had received.


VAERS ID: 682675 (history)  
Form: Version 1.0  
Age: 12.0  
Sex: Female  
Location: New York  
Vaccinated:2016-10-27
Onset:0000-00-00
Submitted: 2017-02-14
Entered: 2017-02-15
   Days after submission:1
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV9: HPV (GARDASIL 9) / MERCK & CO. INC. M028323 / 1 LA / IM

Administered by: Other       Purchased by: Unknown
Symptoms: Blood test, Colonoscopy, Crohn's disease, Endoscopy, Stool analysis, X-ray with contrast upper gastrointestinal tract
SMQs:, Gastrointestinal premalignant disorders (narrow), Ischaemic colitis (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: US0095075131702USA003595

Write-up: This spontaneous report was received from the patient''s mother concerning her 13-year-old daughter. The patient''s pertinent medical history, concurrent conditions, and concomitant therapies were not reported. The patient did not have known allergies or drug reactions. In 26-OCT-2016, the patient was vaccinated with the first dose of an unidentified Merck GARDASIL or GARDASIL 9; 0, 2 months and 6 months; intramuscular (IM) injection (Lot #, expiration date were not provided), for the prevention of human papillomavirus (HPV). The reporter stated that her daughter was diagnosed with Crohn''s disease after receiving her initial injection of GARDASIL or GARDASIL 9 and because of it, she sought medical attention from her pediatrician. On an unspecified date, a blood and fecal laboratory test were performed (results not provided). Later, on 05-DEC-2016, an endoscopy and a colonoscopy were performed (results not provided), and subsequently on 12-DEC-2016, an upper gastrointestinal (GI) exam was performed (results not provided). The reporter stated that her daughter was placed on treatment with PENTASA and prednisone (manufacturer unknown) (unspecified date, strengths, and doses) to treat Crohn''s disease; and in addition, the patient was scheduled to start on infusion therapy with Remicade (manufacturer unknown) (unspecified dose, strength, and dates) also for the treatment of Crohn''s disease. At the time of this report, the patient was recovering from the event of Crohn''s disease. The causal relationship between the event of Crohn''s disease and the therapy with GARDASIL or GARDASIL 9 was not provided. No product quality complaint was involved. Upon internal review, the event of Crohn''s disease was determined to be medically significant. Additional information has been requested.


VAERS ID: 686149 (history)  
Form: Version 1.0  
Age: 49.0  
Sex: Female  
Location: Oregon  
Vaccinated:2017-03-13
Onset:2017-03-13
   Days after vaccination:0
Submitted: 2017-03-16
   Days after onset:3
Entered: 2017-03-16
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
TDAP: TDAP (ADACEL) / SANOFI PASTEUR U5604BA / 2 LA / IM

Administered by: Private       Purchased by: Private
Symptoms: Condition aggravated, Crohn's disease, Diarrhoea haemorrhagic, Pyrexia, Vomiting
SMQs:, Acute pancreatitis (broad), Haemorrhage terms (excl laboratory terms) (narrow), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Pseudomembranous colitis (broad), Gastrointestinal premalignant disorders (narrow), Gastrointestinal haemorrhage (narrow), Gastrointestinal nonspecific symptoms and therapeutic procedures (narrow), Ischaemic colitis (broad), Noninfectious diarrhoea (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: atenolol, vitamin D3, duloxetine, econazole cream, mometasone cream
Current Illness: none
Preexisting Conditions: Allergies: codeine sulfate, iodinate diagnostic agents, sulfa drug cross-reactors. Medical conditions: migraine, hypertension, Crohn''s disease, hypothyroidism, glucose intolerance, obstructive sleep apnea, allergic rhinitis, psoriasis, cystic acne, eczema, rheumatoid arthritis, depresssion, insomnia, anxiety, hirsutism, fatigue
Allergies:
Diagnostic Lab Data:
CDC Split Type:

Write-up: Approximately 12 hours after receiving Tdap patient reported a flare of her Crohn''s disease. She reported bloody diarrhea, vomiting. At 24 hrs after the vaccine she noted a fever of 103. Her PCP Dr advised patient to call back if not starting to improve by the afternoon of 3/16/17. At the time of this report 5:05PM we had not heard from patient. A message was left to check on patient and asked her to call back with an update.


VAERS ID: 716472 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: North Carolina  
Vaccinated:0000-00-00
Onset:2017-09-08
Submitted: 0000-00-00
Entered: 2017-10-05
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HEP: HEP B (RECOMBIVAX HB) / MERCK & CO. INC. - / 2 UN / UN

Administered by: Unknown       Purchased by: ?
Symptoms: Condition aggravated, Crohn's disease, Hepatitis B antibody negative
SMQs:, Gastrointestinal premalignant disorders (narrow), Ischaemic colitis (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: FEMHRT
Current Illness: Breast cancer; Crohn''s disease
Preexisting Conditions: Medical History/Concurrent Conditions: Adverse event
Allergies:
Diagnostic Lab Data:
CDC Split Type: US0095075131710USA000532

Write-up: This spontaneous report was received from a 58 year old female pharmacist referring to herself. The patient''s concurrent conditions included breast cancer and Crohn''s disease. The patient also had unspecified "problems" with REMICADE (manufactured by Janssen) and her concomitant therapies included FEMHRT. On unknown dates, "3 or 4 years ago", the patient was vaccinated with 3 dose series of RECOMBIVAX HB (dose, route of administration, lot number and expiration date were not provided) for prophylaxis. On approximately 08-SEP-2017 (reported as "3 weeks ago), the patient experienced recurrence of unspecified symptoms of her pre-existing Crohn''s disease; therefore, the patient went to her physician, where she was prescribed azathioprine and prednisone (manufacturer unknown) as treatment for these symptoms, she was additionally performed a bloodwork drawn including hepatitis B titers at this visit, which showed that she was negative for immunity to hepatitis B. At the reporting time, the patient had not recovered from the symptoms of her pre-existing Crohn''s disease and the outcome of negative for immunity to hepatitis B was unknown. The causality assessment between RECOMBIVAX HB and the events was not reported. Upon internal review recurrence of unspecified symptoms of the patient''s of Crohn''s disease was considered to be medically significant.


VAERS ID: 718307 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Unknown  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2017-10-10
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
VARCEL: VARICELLA (VARIVAX) / MERCK & CO. INC. - / UNK UN / UN

Administered by: Unknown       Purchased by: ?
Symptoms: Crohn's disease
SMQs:, Gastrointestinal premalignant disorders (narrow), Ischaemic colitis (broad), Immune-mediated/autoimmune disorders (narrow)

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: US0095075131710USA003828

Write-up: This spontaneous report was received from a patient''s father via a company representative and refers to his son -a male patient of unknown age. No information regarding the patient''s pertinent medical history, concurrent conditions and drug reactions or allergies was provided. On an unknown date, the patient was enrolled in an unknown clinical trial and was vaccinated with VARIVAX (dose, route of administration, lot# and expiration date were not reported). On an unknown date, the patient developed Crohn''s disease. The patient was diagnosed at the age of 17 but the father reported that he noticed issues prior the official diagnosis. The outcome of the event was unknown. The relatedness between Crohn''s disease and the suspect drug was not reported. The reporter was wondering whether the event could potentially be related to the patient receiving the vaccine. The reporter mentioned that both of his sons participated in the unknown clinical trial involving VARIVAX. Upon internal review, the event of Crohn''s disease was determined to be medically significant.


Result pages: prev   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15   next

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=6&SYMPTOMS=Crohn%27s_disease_%2810011401%29


Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166